Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Colorectal Neoplasms 6Neoplasm Metastasis 3Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 1HER2 IHC3+ Advanced Colorectal Cancer 1Carcinoma 1Adenocarcinoma 1

Interventions

Carboplatin 17Cisplatin 14Paclitaxel 12Pemetrexed 11pembrolizumab 9Gemcitabine 7Docetaxel 6Sorafenib 5osimertinib 4durvalumab 4130-nm albumin-bound paclitaxel 4padeliporfin 3cabozantinib 3atezolizumab 3Taxes 3Radiotherapy 3Mitomycin 3Magnetic Resonance Spectroscopy 3Cetuximab 3Bevacizumab 31-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 3trifluridine tipiracil drug combination 2regorafenib 2olaparib 2Sunitinib 2Specimen Handling 2Radiotherapy, Intensity-Modulated 2Radiation 2Nivolumab 2Irinotecan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Carcinoma × Trifluridine × Clear all
NCT04879368 2025-07-17

INTEGRATEIIb

Australasian Gastro-Intestinal Trials Group

Phase 3 Active not recruiting
450 enrolled
Tumor-Agnostic

Adenocarcinoma, Carcinoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡